In breast cancer, concurrent amplification of the CDK12 and ERBB2 genes has been described in ductal type NST carcinomas and in association with poor prognosis, worse response to anti‐HER2 treatment and also resistance to endocrine therapy [24, 25, 26, 27, 28]. This evidence concerns the gene CDK12 and breast carcinoma.